All In Biotech

Drug Trial Radar · NCT03655678

A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia

A Phase 1/2/3 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in Subjects With Transfusion-Dependent β-Thalassemia

Last checked: Nov 19, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

59

Actual

Start

Sep 14, 2018

Primary completion

Nov 13, 2025

Study completion Nov 13, 2025

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
Collaborators
CRISPR Therapeutics
First posted
Aug 31, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-arm, open-label, multi-site, single-dose Phase 1/2/3 study in participans with transfusion-dependent β-thalassemia (TDT). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) using CTX001.

Conditions

  • Beta-Thalassemia
  • Thalassemia
  • Genetic Diseases, Inborn
  • Hematologic Diseases
  • Hemoglobinopathies

Interventions

  • CTX001Biological

    Administered by IV infusion following myeloablative conditioning with busulfan

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants achieving transfusion independence for at least 12 consecutive months (TI12)Time frame: From 60 days after last RBC transfusion up to 24 months post-CTX001 infusion]
  2. Proportion of participants with engraftment (first day of 3 consecutive measurements of absolute neutrophil count [ANC] ≥500/µL on three different days)Time frame: Within 42 days after CTX001 infusion
  3. Time to neutrophil and platelet engraftmentTime frame: Days post-infusion to engraftment
  4. Frequency and severity of collected adverse events (AEs)Time frame: Signing of informed consent through Month 24 visit
  5. Incidence of transplant-related mortality (TRM)Time frame: Baseline (pre-transfusion) to 100 days and 1 year post-CTX001 infusion
  6. All-cause mortalityTime frame: Signing of informed consent through Month 24 visit

Locations

14 sites in 5 countries. Site status is shown where the registry gives one.

  • Lucile Packard Children's Hospital

    Palo Alto, California

  • Ann & Robert Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Columbia University Medical Center (21+ years)

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • The Children's Hospital at TriStar Centennial Medical Center/ Sarah Cannon Center for Blood Cancers

    Nashville, Tennessee

  • The Hospital for Sick Children

    Toronto, Canada

  • British Columbia Children's Hospital

    Vancouver, Canada

  • Universitätsklinikum Düsseldorf Hospital Duesseldorf

    Düsseldorf, Germany

  • Regensburg University Hospital, Clinic and Polyclinic for Paediatric and Adolescent Medicine

    Regensburg, Germany

  • University Hospital Tübingen

    Tübingen, Germany

  • Ospedale Pediatrico Bambino Gesù, IRCCS

    Rome, Italy

  • Imperial College Healthcare NHS Trust, Hammersmith Hospital

    London, United Kingdom

  • University College London Hospitals NHS Foundation Trust

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.